Drug-Eluting Surgical Sutures with Controlled Local Pharmacokinetics: A Comprehensive Review

Abstract

Drug-eluting surgical sutures represent a significant advancement in perioperative care, offering targeted and sustained delivery of pharmacological agents directly to the site of tissue repair. This review provides a comprehensive examination of the rationale, mechanisms, and clinical implications of drug-eluting sutures with controlled local pharmacokinetics, highlighting their role in optimizing surgical outcomes, minimizing complications, and aligning with current evidence-based surgical guidelines.

Introduction

Surgical site infection (SSI) and impaired wound healing remain persistent challenges in operative medicine, often resulting in increased morbidity, extended hospital stays, and healthcare costs. The concept of combining mechanical closure with localized pharmacological intervention has led to the development of drug-eluting surgical sutures. By integrating pharmaceutical agents within suture material, these platforms enable precise drug delivery, reduce systemic exposure, and potentially enhance wound healing. Recent technological advances in material science and pharmacokinetics have catalyzed the evolution of sutures capable of releasing antibiotics, anti-inflammatory agents, and growth factors in a controlled manner, tailored to the wound’s healing trajectory.

Epidemiology / Disease Burden

SSIs are among the most common postoperative complications, with reported incidences ranging from 2% to 20% depending on the surgical procedure and patient risk profile. The financial burden is substantial, with SSIs contributing to billions in additional healthcare expenditures globally each year. Furthermore, the prevalence of antimicrobial-resistant organisms in surgical wounds underscores the need for innovative prophylactic strategies. Drug-eluting sutures, by delivering high local concentrations of antimicrobials, may address this burden by reducing infection rates and mitigating the consequences of systemic antibiotic resistance.

Pathophysiology

The wound healing process is a complex orchestration of hemostasis, inflammation, proliferation, and remodeling, susceptible to disruption by microbial contamination, excessive inflammation, and impaired angiogenesis. Traditional sutures act as foreign bodies and can serve as niduses for bacterial colonization, potentially leading to biofilm formation and persistent infection. Drug-eluting sutures are engineered to counteract these pathophysiological processes by releasing active agents that inhibit microbial adhesion, modulate inflammation, and promote tissue regeneration at the suture-tissue interface.

Risk Factors

Multiple patient- and procedure-related factors contribute to adverse wound healing and SSI risk, including diabetes mellitus, obesity, immunosuppression, advanced age, contaminated surgical fields, and prolonged operative times. The use of indwelling foreign materials (e.g., sutures, prostheses) further amplifies infection risk. Incorporating drug-eluting technology into suture design directly addresses these risk factors by providing site-specific pharmacological prophylaxis, especially in high-risk populations and contaminated or complex surgical wounds.

Clinical Features

Clinically, SSIs may manifest as local erythema, induration, pain, purulent discharge, fever, or delayed wound healing. Subclinical colonization of standard sutures may go undetected until overt infection develops. Drug-eluting sutures aim to reduce the incidence and severity of such complications, leading to more predictable wound healing trajectories, decreased rates of dehiscence, and improved patient outcomes.

Diagnosis

Diagnosis of wound complications relies on clinical assessment complemented by laboratory markers (e.g., elevated leukocyte count, C-reactive protein) and imaging when deep space infections are suspected. Microbiological cultures of wound exudate or suture material may reveal causative organisms. Future diagnostic advancements may include monitoring local drug concentrations or biomarkers of healing in situ, particularly in the context of drug-eluting suture use.

Treatment & Management

Current management of SSIs includes systemic antibiotic therapy, wound debridement, and sometimes suture removal. Preventive measures emphasize aseptic technique, perioperative systemic antibiotic prophylaxis, and careful wound care. Drug-eluting sutures offer an adjunct or alternative by maintaining high local antimicrobial concentrations at the wound site, potentially obviating systemic side effects and improving prophylactic efficacy. In addition, incorporating anti-inflammatory or pro-healing agents may further optimize tissue repair and functional recovery.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the design and composition of drug-eluting sutures. Biodegradable polymers such as polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL) are employed as matrices to control the release kinetics of embedded drugs. Antibiotic-eluting sutures (e.g., triclosan-coated) have demonstrated efficacy in reducing SSI rates in several randomized controlled trials. Emerging platforms now incorporate growth factors (e.g., platelet-derived growth factor), analgesics, and antiadhesive agents, enabling multifaceted modulation of the wound microenvironment. Nanotechnology-based suture coatings and stimuli-responsive release systems represent the forefront of research, promising even more precise temporal and spatial control over drug delivery.

Guideline Recommendations

Major surgical and infection control guidelines, including those from the World Health Organization and Centers for Disease Control and Prevention, endorse the use of antimicrobial-coated sutures in specific high-risk procedures to reduce SSI incidence. The selection of suture type and drug-eluting characteristics should be individualized based on patient risk assessment, wound classification, and local microbial resistance patterns. Ongoing updates to guidelines increasingly reflect the growing body of evidence supporting the integration of drug-eluting suture technology into standard surgical practice, particularly in contaminated or high-risk settings.

Conclusion

Drug-eluting surgical sutures with controlled local pharmacokinetics represent a paradigm shift in the prevention and management of surgical wound complications. Their capacity to deliver precisely titrated pharmacological agents directly to the wound site offers distinct advantages in reducing infection, modulating inflammation, and promoting optimal healing. Continued innovation in suture material science, pharmacology, and clinical application, guided by robust evidence and multidisciplinary collaboration, will further define the role of these advanced devices in modern surgical practice. As the landscape of surgery evolves, drug-eluting sutures stand poised to become integral components of comprehensive perioperative care.